Table 2.
Prevalence of mutations in dhfr and dhps in Senegal and Tanzania: monogenomic, polygenomic, and combined
| Genes | Alleles | Monogenomic infections | Polygenomic infections | Combined Prevalence of mutations | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Senegal | Tanzania | p value | Senegal | Tanzania | p value | Senegal | Tanzania | p value | ||
| DHPS 437 | A437 | 10/23 (43.47%) | 6/14 (42.86%) | 0.9681 | 8/27 (29.62%) | 12/36 (33.33%) | 0.75656 | 18/50 (36%) | 18/50 (36%) | 1 |
| G437 | 12/23 (52.17%) | 6/14 (42.86%) | 0.58 | 16/27 (59.25%) | 11/36 (30.56%) | 0.0226 | 28/50 (56%) | 17/50 (34%) | 0.0271 | |
| A437 + G437 | 1/23 (4.34%) | 2/14 (14.29%) | 0.28 | 3/27 (11.11%) | 13/36 (36.11%) | 0.02382 | 4/50 (8%) | 15/50 (30%) | 0.00512 | |
| DHPS 540 | K540 | 23/23 (100%) | 14/14 (100%) | ≥0.05 | 27/27 (100%) | 36/36 (100%) | ≥0.05 | 50/50 (100%) | 50/50 (100%) | ≥0.05 |
| E540 | 0/23 (0%) | 0/14 (0%) | ≥0.05 | 0/27 (0%) | 0/36 (0%) | ≥0.05 | 0 | 0 | ≥0.05 | |
| K540 + E540 | 0/23 (0%) | 0/14 (0%) | ≥0.05 | 0/27 (0%) | 0/36 (0%) | ≥0.05 | 0 | 0 | ≥0.05 | |
| DHPS 581 | A581 | 23/23 (100%) | 14/14 (100%) | ≥0.05 | 27/27 (100%) | 36/36 (100%) | ≥0.05 | 50/50 (100%) | 50/50 (100%) | ≥0.05 |
| G581 | 0/23 (0%) | 0/14 (0%) | ≥0.05 | 0/27 (0%) | 0/36 (0%) | ≥0.05 | 0 | 0 | ≥0.05 | |
| A581 + G581 | 0/23 (0%) | 0/14 (0%) | ≥0.05 | 0/27 (0%) | 0/36 (0%) | ≥0.05 | 0 | 0 | ≥0.05 | |
| DHPS 613 | A613 | 21/23 (91.30%) | 14/14 (100%) | 0.25848 | 26/27 (96.29%) | 36/36 (100%) | ≥0.05 | 46/50 (92%) | 49/50 (98%) | 0.16758 |
| T/S613 | 1/23 (3.33%) | 0/14 (0%) | 0.42952 | 0/27 (0%) | 0/36 (0%) | ≥0.05 | 2/50 (4%) | 0 | 0.15272 | |
| A613 + T/S613 | 1/23 (3.33%) | 0/14 (0%) | 0.42952 | 1/27 (3.7%) | 0/36 (0%) | 0.24604 | 2/50 (4%) | 1/50 (2%) | 0.5552 | |
| DHFR 51 | N51 | 0/23 (0%) | 4/14 (28.57%) | 0.00672 | 0/27 (0%) | 4/36 (11.12%) | 0.07346 | 0 | 09/50 (18%) | 0.00168 |
| 51I | 20/23 (86.95%) | 4/14 (28.57%) | 0.0003 | 27/27 (100%) | 22/36 (61.12%) | 0.00024 | 47/50 (94%) | 37/50 (74%) | 0.00634 | |
| N51 + 51I | 3/23 (13.04%) | 6/14 (42.86%) | 0.04036 | 0/27 (0%) | 10/36 (27.78%) | 0.00278 | 3/50 (6%) | 04/50 (08%) | 0.69654 | |
| DHFR 59 | C59 | 0/23 (0%) | 4/14 (22.57%) | 0.00672 | 1/27 (3.70%) | 8/36 (22.22%) | 0.03752 | 1/50 (2%) | 19/50 (38%) | 0 |
| 59R | 20/23 (86.95%) | 4/14 (22.57%) | 0.0003 | 26/27 (96.29%) | 18/36 (50%) | 0.0001 | 46/50 (92%) | 24/50 (48%) | 0 | |
| C59 + 59R | 3/23 (13.04%) | 6/14 (42.86%) | 0.04036 | 0/27 (0%) | 10/36 (27.78%) | 0.0088 | 3/50 (6%) | 07/50 (14%) | 0.18352 | |
| DHFR 108 | S108 | 0/23 (0%) | 5/14 (35.71%) | 0.00208 | 0/27 (0%) | 2/36 (5.55%) | 0.21498 | 0 | 07/50 (14%) | 0.00614 |
| N108 | 22/23 (95.65%) | 9/14 (64.29%) | 0.01208 | 27/27 (100%) | 29/36 (80.56%) | 0.0151 | 49/50 (98%) | 35/50 (70%) | 0.00014 | |
| S108 + N108 | 1/23 (4.35%) | 0/14 (0%) | 0.42952 | 0/27 (0%) | 5/36 (13.89%) | 0.04338 | 1/50 (2%) | 08/50 (16%) | 0.01428 | |
Msp-1 and Msp-2 typing data were combined with drug resistance allele typing to determine the prevalence of mutations at each codon in monogenomic, polygenomic. The z-test for 2 population proportions was used to compare the allele prevalence in each country. The test is significant if the p value is less than 0.05